Hib-meningococcal vaccine groups A and C polysaccharide conjugate - Chongqing Zhifei Biological Products

Drug Profile

Hib-meningococcal vaccine groups A and C polysaccharide conjugate - Chongqing Zhifei Biological Products

Alternative Names: HibACon; MenAC-Hib - Chongqing Zhifei Biological Products; MenAC-Hib polysaccharide conjugate vaccine

Latest Information Update: 06 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Chongqing Zhifei Biological Products
  • Class Haemophilus vaccines; Meningococcal vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Haemophilus infections; Meningococcal group A infections; Meningococcal group C infections

Most Recent Events

  • 01 Aug 2016 Phase-I/II clinical trials in Haemophilus infections, Meningococcal group A infections and Meningococcal group C infections (Prevention, In infants) in China (IM) (NCT02919293)
  • 05 Jun 2015 Phase III development is ongoing in China
  • 30 Oct 2012 Phase-III clinical trials in Haemophilus infections (Prevention) in China (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top